The Library
RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia
Tools
Gassner, Franz, Zaborsky, Nadja, Buchumenski, Ilana, Levanon, Erez, Gatterbauer, Matthias, Schubert, Maria, Rauscher, Stefanie, Hebenstreit, Daniel, Nadeu, Ferran, Campo, Elias, Egle, Alexander, Greil, Richard and Geisberger, Roland (2021) RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. Leukemia, 35 . pp. 1053-1063. doi:10.1038/s41375-020-0995-6 ISSN 0887-6924.
|
PDF
WRAP-RNA-editing-contributes-epitranscriptome-diversity-chronic-lymphocytic-leukemia-Hebenstreit-2020.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (2627Kb) | Preview |
|
PDF
WRAP-RNA-editing-contributes-epitranscriptome-diversity-chronic-lymphocytic-leukemia-Hebenstreit-2020.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer. Download (3279Kb) |
Official URL: https://doi.org/10.1038/s41375-020-0995-6
Abstract
RNA editing—primarily conversion of adenosine to inosine (A > I)—is a widespread posttranscriptional mechanism, mediated by Adenosine Deaminases acting on RNA (ADAR) enzymes to alter the RNA sequence of primary transcripts. Hence, in addition to somatic mutations and alternative RNA splicing, RNA editing can be a further source for recoding events. Although RNA editing has been detected in many solid cancers and normal tissue, RNA editing in chronic lymphocytic leukemia (CLL) has not been addressed so far. We determined global RNA editing and recurrent, recoding RNA editing events from matched RNA-sequencing and whole exome sequencing data in CLL samples from 45 untreated patients. RNA editing was verified in a validation cohort of 98 CLL patients and revealed substantially altered RNA editing profiles in CLL compared with normal B cells. We further found that RNA editing patterns were prognostically relevant. Finally, we showed that ADAR knockout decreased steady state viability of MEC1 cells and made them more susceptible to treatment with fludarabine and ibrutinib in vitro. We propose that RNA editing contributes to the pathophysiology of CLL and targeting the RNA editing machinery could be a future strategy to maximize treatment efficacy.
Item Type: | Journal Article | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QH Natural history > QH426 Genetics R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
|||||||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) | |||||||||||||||
Library of Congress Subject Headings (LCSH): | RNA editing, Genetic regulation, Chronic lymphocytic leukemia | |||||||||||||||
Journal or Publication Title: | Leukemia | |||||||||||||||
Publisher: | Nature Publishing Group | |||||||||||||||
ISSN: | 0887-6924 | |||||||||||||||
Official Date: | April 2021 | |||||||||||||||
Dates: |
|
|||||||||||||||
Volume: | 35 | |||||||||||||||
Page Range: | pp. 1053-1063 | |||||||||||||||
DOI: | 10.1038/s41375-020-0995-6 | |||||||||||||||
Status: | Peer Reviewed | |||||||||||||||
Publication Status: | Published | |||||||||||||||
Access rights to Published version: | Open Access (Creative Commons) | |||||||||||||||
Date of first compliant deposit: | 23 July 2020 | |||||||||||||||
Date of first compliant Open Access: | 22 September 2020 | |||||||||||||||
RIOXX Funder/Project Grant: |
|
|||||||||||||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year